emrelis - telisotuzumab vedotin injection, powder, lyophilized, for solution
(Telisotuzumab Vedotin)Abbvie Inc.
Usage: Emrelis treats adults with locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression (≥50% of tumor cells, 3+ staining) who have received prior systemic therapy. Approved under accelerated approval based on overall response rate and duration of response.